News Release

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

KemPharm to Present at Upcoming Investor Conferences

March 6, 2018 at 7:30 AM EST

Presentations to Highlight Corporate and Clinical Progress

CORALVILLE, Iowa, March 06, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and Chief Executive Officer, Travis Mickle, Ph.D., will present at the following investor conferences during the month of March.

Details of KemPharm's presentations are as follows:

Event:   Cowen and Company 38th Annual Health Care Conference 2018
Date:    Monday, March 12, 2018
Time:    12:00 PM (ET)
Location:   The Boston Marriott Copley Place, Boston, MA
Room:   Regis
Event:   29th Annual ROTH Conference
Date:    March 13, 2018
Time:    11:30 AM (PT)
Location:   The Ritz Carlton, Dana Point, CA
Room:   Blue – Salon 2
Event:   Oppenheimer & Co. 28th Annual Healthcare Conference
Date:    March 20, 2018
Time:    10:20 AM (ET)
Location:   The Westin New York Grand Central, New York, NY
Room:   Track 3

All presentation webcasts will be available on the Investor Relations section of the KemPharm website at following delivery at the respective conferences.

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) platform technology.  KemPharm utilizes its proprietary LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD, pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD.  In addition, the company has received FDA approval for Apadaz™, an immediate-release combination product candidate of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.  The company is also advancing KP201/IR, an acetaminophen-free immediate-release formulation of the company’s benzhydrocodone prodrug candidate. Both Apadaz and KP201/IR are intended for the treatment of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. For more information on KemPharm and its pipeline of prodrug product candidates visit

Investor Contacts:  Media Contact:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
Daniel L. Cohen
Executive VP, Government and Public Relations
KemPharm, Inc.

Primary Logo

Source: KemPharm